Cargando…

Long-term survival outcomes of esophageal cancer after minimally invasive Ivor Lewis esophagectomy

OBJECTIVES: The aim of this study was to determine the long-term overall and disease-free survival and factors associated with overall survival in patients with esophageal cancer undergoing a totally minimally invasive Ivor Lewis esophagectomy (MILE) at a safety-net hospital. METHODS: This was a sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Pather, Keouna, Mobley, Erin M., Guerrier, Christina, Esma, Rhemar, Kendall, Heather, Awad, Ziad T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876443/
https://www.ncbi.nlm.nih.gov/pubmed/35209914
http://dx.doi.org/10.1186/s12957-022-02518-0
_version_ 1784658176244711424
author Pather, Keouna
Mobley, Erin M.
Guerrier, Christina
Esma, Rhemar
Kendall, Heather
Awad, Ziad T.
author_facet Pather, Keouna
Mobley, Erin M.
Guerrier, Christina
Esma, Rhemar
Kendall, Heather
Awad, Ziad T.
author_sort Pather, Keouna
collection PubMed
description OBJECTIVES: The aim of this study was to determine the long-term overall and disease-free survival and factors associated with overall survival in patients with esophageal cancer undergoing a totally minimally invasive Ivor Lewis esophagectomy (MILE) at a safety-net hospital. METHODS: This was a single-center retrospective review of consecutive patients who underwent MILE from September 2013 to November 2017. Overall and disease-free survival were analyzed by Kaplan-Meier estimates, and hazard ratios (HR) were derived from multivariable Cox regression models. RESULTS: Ninety-six patients underwent MILE during the study period. Overall survival at 1, 3, and 5 years was 83.2%, 61.9%, and 55.9%, respectively. Disease-free survival at 1, 3, and 5 years was 83.2%, 60.6%, and 47.5%, respectively. Overall survival (p < 0.001) and disease-free survival (p < 0.001) differed across pathological stages. By multivariable analysis, increasing age (HR, 1.06; p = 0.02), decreasing Karnofsky performance status score (HR, 0.94; p = 0.002), presence of stage IV disease (HR, 5.62; p = 0.002), locoregional recurrence (HR, 2.94; p = 0.03), and distant recurrence (HR, 4.78; p < 0.001) were negatively associated with overall survival. Overall survival significantly declined within 2 years and was independently associated with stage IV disease (HR, 3.29; p = 0.04) and distant recurrence (HR, 5.78; p < 0.001). CONCLUSION: MILE offers favorable long-term overall and disease-free survival outcomes. Age, Karnofsky performance status score, stage IV, and disease recurrence are shown to be prognostic factors of overall survival. Prospective studies comparing long-term outcomes after different MIE approaches are warranted to validate survival outcomes after MILE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-022-02518-0.
format Online
Article
Text
id pubmed-8876443
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88764432022-02-28 Long-term survival outcomes of esophageal cancer after minimally invasive Ivor Lewis esophagectomy Pather, Keouna Mobley, Erin M. Guerrier, Christina Esma, Rhemar Kendall, Heather Awad, Ziad T. World J Surg Oncol Review OBJECTIVES: The aim of this study was to determine the long-term overall and disease-free survival and factors associated with overall survival in patients with esophageal cancer undergoing a totally minimally invasive Ivor Lewis esophagectomy (MILE) at a safety-net hospital. METHODS: This was a single-center retrospective review of consecutive patients who underwent MILE from September 2013 to November 2017. Overall and disease-free survival were analyzed by Kaplan-Meier estimates, and hazard ratios (HR) were derived from multivariable Cox regression models. RESULTS: Ninety-six patients underwent MILE during the study period. Overall survival at 1, 3, and 5 years was 83.2%, 61.9%, and 55.9%, respectively. Disease-free survival at 1, 3, and 5 years was 83.2%, 60.6%, and 47.5%, respectively. Overall survival (p < 0.001) and disease-free survival (p < 0.001) differed across pathological stages. By multivariable analysis, increasing age (HR, 1.06; p = 0.02), decreasing Karnofsky performance status score (HR, 0.94; p = 0.002), presence of stage IV disease (HR, 5.62; p = 0.002), locoregional recurrence (HR, 2.94; p = 0.03), and distant recurrence (HR, 4.78; p < 0.001) were negatively associated with overall survival. Overall survival significantly declined within 2 years and was independently associated with stage IV disease (HR, 3.29; p = 0.04) and distant recurrence (HR, 5.78; p < 0.001). CONCLUSION: MILE offers favorable long-term overall and disease-free survival outcomes. Age, Karnofsky performance status score, stage IV, and disease recurrence are shown to be prognostic factors of overall survival. Prospective studies comparing long-term outcomes after different MIE approaches are warranted to validate survival outcomes after MILE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-022-02518-0. BioMed Central 2022-02-25 /pmc/articles/PMC8876443/ /pubmed/35209914 http://dx.doi.org/10.1186/s12957-022-02518-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Pather, Keouna
Mobley, Erin M.
Guerrier, Christina
Esma, Rhemar
Kendall, Heather
Awad, Ziad T.
Long-term survival outcomes of esophageal cancer after minimally invasive Ivor Lewis esophagectomy
title Long-term survival outcomes of esophageal cancer after minimally invasive Ivor Lewis esophagectomy
title_full Long-term survival outcomes of esophageal cancer after minimally invasive Ivor Lewis esophagectomy
title_fullStr Long-term survival outcomes of esophageal cancer after minimally invasive Ivor Lewis esophagectomy
title_full_unstemmed Long-term survival outcomes of esophageal cancer after minimally invasive Ivor Lewis esophagectomy
title_short Long-term survival outcomes of esophageal cancer after minimally invasive Ivor Lewis esophagectomy
title_sort long-term survival outcomes of esophageal cancer after minimally invasive ivor lewis esophagectomy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876443/
https://www.ncbi.nlm.nih.gov/pubmed/35209914
http://dx.doi.org/10.1186/s12957-022-02518-0
work_keys_str_mv AT patherkeouna longtermsurvivaloutcomesofesophagealcancerafterminimallyinvasiveivorlewisesophagectomy
AT mobleyerinm longtermsurvivaloutcomesofesophagealcancerafterminimallyinvasiveivorlewisesophagectomy
AT guerrierchristina longtermsurvivaloutcomesofesophagealcancerafterminimallyinvasiveivorlewisesophagectomy
AT esmarhemar longtermsurvivaloutcomesofesophagealcancerafterminimallyinvasiveivorlewisesophagectomy
AT kendallheather longtermsurvivaloutcomesofesophagealcancerafterminimallyinvasiveivorlewisesophagectomy
AT awadziadt longtermsurvivaloutcomesofesophagealcancerafterminimallyinvasiveivorlewisesophagectomy